Nuclear Factor Kappa‐B Inducing Kinase‐ and Inhibitor of Nuclear Factor Kappa‐B Kinase Subunit Beta‐Binding Protein Promotes Pathological Cardiac Hypertrophy by Regulating Inhibitor of Nuclear Factor Kappa‐B Kinase Subunit Beta‐Mediated Nuclear Factor Kappa‐B Activation

@article{xie2026nuclear,
  title = {{Nuclear Factor Kappa‐B Inducing Kinase‐ and Inhibitor of Nuclear Factor Kappa‐B Kinase Subunit Beta‐Binding Protein Promotes Pathological Cardiac Hypertrophy by Regulating Inhibitor of Nuclear Factor Kappa‐B Kinase Subunit Beta‐Mediated Nuclear Factor Kappa‐B Activation}},
  author = {Zheng Xie and Yingjie Zuo and Mengyao Wang and Xin Zhang and Lirong Zhang and Zixuan Liu and Bilong Zhang and Zhaohai Su and Saichao Yang and Hailong Yang and Jianqing Zhang and Zhonghan Ni and Hui Liu and Fang Pei},
  journal = {Journal of the American Heart Association},
  year = {2026},
  month = oct,
  doi = {10.1161/jaha.125.046637},
  url = {https://www.ahajournals.org/doi/10.1161/JAHA.125.046637},
  note = {CC BY-NC-ND},
}

TY  - JOUR
TI  - Nuclear Factor Kappa‐B Inducing Kinase‐ and Inhibitor of Nuclear Factor Kappa‐B Kinase Subunit Beta‐Binding Protein Promotes Pathological Cardiac Hypertrophy by Regulating Inhibitor of Nuclear Factor Kappa‐B Kinase Subunit Beta‐Mediated Nuclear Factor Kappa‐B Activation
AU  - Zheng Xie
AU  - Yingjie Zuo
AU  - Mengyao Wang
AU  - Xin Zhang
AU  - Lirong Zhang
AU  - Zixuan Liu
AU  - Bilong Zhang
AU  - Zhaohai Su
AU  - Saichao Yang
AU  - Hailong Yang
AU  - Jianqing Zhang
AU  - Zhonghan Ni
AU  - Hui Liu
AU  - Fang Pei
PY  - 2026
DA  - 2026/10/23
JO  - Journal of the American Heart Association
DO  - 10.1161/jaha.125.046637
UR  - https://www.ahajournals.org/doi/10.1161/JAHA.125.046637
AB  - Background Pathological cardiac hypertrophy is a major risk factor for heart failure. NIBP (NF‐κB [nuclear factor kappa‐B] inducing kinase‐ and inhibitor of NF‐κB kinase subunit beta‐binding protein) is a key regulator of cytokine‐induced NF‐κB signaling, but its role in cardiac hypertrophy remains unknown. Methods We established transverse aortic constriction‐induced cardiac hypertrophy in mice and phenylephrine‐induced hypertrophy in neonatal rat ventricular myocytes. Genetic interventions included generation of whole‐body Nibp knockout mice via CRISPR‐Cas9; creation of cardiomyocyte‐specific Nibp knockout mice using adeno‐associated virus serotype 9‐delivered Cre and single‐guide RNAs in Rosa26‐LSL‐Cas9 mice; and cardiac‐specific Nibp overexpression via adeno‐associated virus serotype 9delivery. In neonatal rat ventricular myocytes, NIBP was knocked down or overexpressed using adenoviruses. Phenotypes were assessed by echocardiography, histology (wheat germ agglutinin, picrosirius redstaining), and molecular analyses. Mechanisms were investigated via RNA‐sequencing, coimmunoprecipitation, and Western blotting for key signaling molecules. Results NIBP protein was upregulated in hypertrophic hearts and cardiomyocytes. Both Nibp ‐knockout and cardiomyocyte‐specific Nibp knockout attenuated transverse aortic constriction‐induced cardiac dysfunction, hypertrophy, and fibrosis, whereas Nibp overexpression exacerbated these pathologies. Consistently, in neonatal rat ventricular myocytes, NIBP knockdown mitigated, while its overexpression aggravated, phenylephrine‐induced cardiomyocyte hypertrophy and inflammatory responses. Mechanistically, NIBP directly interacted with IKKβ (inhibitor of NF‐κB kinase subunit beta), enhanced its phosphorylation, and drove hyperactivation of the downstream NF‐κB pathway. Overexpression of a kinase‐dead IKKβ mutant reversed the hypertrophic effects of NIBP. Conclusions NIBP promotes pathological cardiac hypertrophy by activating the IKKβ/NF‐κB axis, identifying it as a potential therapeutic target for cardiac remodeling and heart failure.
SN  - 2047-9980
ER  -